Antibody therapeutic (second) - Bayer HealthCare/BioInvent International
Latest Information Update: 28 Jul 2018
Price :
$50 *
At a glance
- Originator Bayer HealthCare
- Developer Bayer HealthCare; BioInvent International
- Class Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for phase-I development in Undefined in Germany (Parenteral)
- 11 Sep 2014 Phase-I clinical trials in Undefined indication in Germany (Parenteral)